Corvus Pharmaceuticals Inc (NASDAQ:CRVS) CEO Richard A. Md Miller purchased 100,000 shares of the company’s stock in a transaction on Monday, March 12th. The shares were bought at an average price of $8.50 per share, for a total transaction of $850,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Corvus Pharmaceuticals Inc (CRVS) traded down $0.10 during mid-day trading on Monday, hitting $9.78. 76,111 shares of the company’s stock were exchanged, compared to its average volume of 115,004. Corvus Pharmaceuticals Inc has a one year low of $7.42 and a one year high of $22.14.
Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings results on Thursday, March 1st. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.18. sell-side analysts anticipate that Corvus Pharmaceuticals Inc will post -3.15 earnings per share for the current fiscal year.
A number of analysts have commented on the stock. Zacks Investment Research downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. Cowen restated a “buy” rating on shares of Corvus Pharmaceuticals in a research report on Friday, March 2nd. Finally, ValuEngine downgraded shares of Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $20.25.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/03/12/insider-buying-corvus-pharmaceuticals-inc-crvs-ceo-buys-100000-shares-of-stock.html.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.